Last updated on June 2020

ISTODAX for Intravenous Infusion Drug Use Results Survey- Relapsed or Refractory Peripheral T-Cell Lymphoma

Brief description of study

To ascertain the safety and efficacy of Istodax in actual clinical settings in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL) who receive Istodax.

  1. Planned registration period 3 years and 6 months
  2. Planned surveillance period 4 years and 6 months

Clinical Study Identifier: NCT03742921

Find a site near you

Start Over

Nihon Seimei Hospital

Osaka, Japan
  Connect »

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.